Home \ Therapy \ Rehabilitation after COVID-19: the use of Mexidol® in the treatment of post-COVID disorders

Rehabilitation after COVID-19: the use of Mexidol® in the treatment of post-COVID disorders

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Neurological symptoms after coronavirus infection
04:49
Multidisciplinary management of patients with COVID-19
06:00
Safety of breathing exercises with pulmonary failure
09:25
Features of the selection of therapy in patients with post -shoe syndrome
12:00
The main mechanisms of the development of complications
12:35
Mexidol® - multimodal neurocytoprotector
15:53
The use of Mexidol® in the treatment of post -shoe disorders
18:00
Clinical examination of the use of Mexidol® in patients with COVID-19

Evgeniya Viktorovna Yekusheva – Doctor of Medical Sciences, Professor, Head of the Department of Nervous System Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia

Vitaly Vladimirovich Kovalchuk – Doctor of Medical Sciences, Professor, Chairman of the Society of Rehabilitation Specialists of St. Petersburg, Head of the Department of Neurological Rehabilitation of the St. Petersburg State Budgetary Healthcare Institution “City Hospital No. 38 named after N.A. Semashko”

Announcement:

Oxidative stress and energy deficiency are the primary mechanisms underlying the pathogenesis of neurological disorders following coronavirus infection. Therefore, antioxidants, antihypoxants, and energy-correcting medications are essential for patients who have recovered from COVID-19. Mexidol®is a pathogenetically proven drug that helps treat neurological disorders. Mexidol®, by restoring mitochondrial energy-synthesizing function and neutralizing oxidative stress in nervous tissue, reduces the severity of asthenia and improves sleep and cognitive function after coronavirus infection. Studies of Mexidol® have shown that it also reduces the symptoms of chronic cerebral ischemia, improving the quality of life of patients who have recovered from coronavirus infection.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:00
Neurological symptoms after coronavirus infection
04:49
Multidisciplinary management of patients with COVID-19
06:00
Safety of breathing exercises with pulmonary failure
09:25
Features of the selection of therapy in patients with post -shoe syndrome
12:00
The main mechanisms of the development of complications
12:35
Mexidol® - multimodal neurocytoprotector
15:53
The use of Mexidol® in the treatment of post -shoe disorders
18:00
Clinical examination of the use of Mexidol® in patients with COVID-19

Block of articles on this topic

The effectiveness of Mexidol Correction in the correction of the post -shoe syndrome in patients with chronic cerebrovascular diseases

Authors:

E.B. Kuznetsova, E.A. Salina, N.S. Kuznetsov

FSBEI in "Saratov State Medical University named after V.I. Razumovsky "Ministry of Health of Russia, Saratov, Russia

Personal: The role of antioxidant therapy in patients with a new coronavirus infection of COVID-19 of moderate and severe course

Authors:
E.K. SHAVAROVA^1,2, E.R. KAZAKHMEDOV¹, M.V. ALEXEEVA¹, L.G. EZHOVA², Zh.D. KOBALAVA¹

¹Peoples' Friendship University of Russia (RUDN University), Moscow, Russian Federation;
²Vinogradov City Clinical Hospital, Moscow Department of Health, Moscow, Russian Federation

Personal: the role of free-radical oxidation, hypoxia and their correction in the pathogenesis of Covid-19

Authors:
A.V. SHCHULKIN, A.A. FILIMONOVA

FGBOU in the Ryazan State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia

Clinical and psychological profile and quality of life of patients with post-shoe syndrome

Authors:
L. V. CHICHANOVSKAYA, T. A. SLYUSAR, Yu. V. ABRAMENKO, T. M. NEKRASOVA, I. N. SLYUSAR

FSBEI in the Tver State Medical University of the Ministry of Health of Russia, Tver, Russia

Neurological manifestations of post -shoe syndrome

Authors:

P.R. KAMCHATNOV¹, R.A. CHEREMIN², L.A. SKIPETROVA², A.V. CHUGUNOV¹

¹Federal State Budgetary Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russia;
²State Budgetary Healthcare Institution “Speech Pathology and Neurorehabilitation Center of the Moscow Department of Health”, Moscow, Russia.

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com